We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04646603
Recruitment Status : Recruiting
First Posted : November 30, 2020
Last Update Posted : February 15, 2022
Sponsor:
Collaborators:
ICON plc
Johns Hopkins University
Information provided by (Responsible Party):
MedRegen LLC

Brief Summary:

This study consists of two parts.

Part A (Phase I):

A Phase I Double-blind Randomized Placebo-controlled Study in Healthy Subjects to Assess the Safety, Pharmacokinetics, Pharmacodynamics of MRG-001

Part B (Phase 2):

A Phase IIa, Adaptive, Double-Blind, Randomized, Placebo-controlled, Multi-center Study in Hospitalized Patients Infected with Severe and Critical SARS-CoV-2 to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001


Condition or disease Intervention/treatment Phase
COVID-19 ARDS, Human Stem Cells Regeneration Drug: MRG-001 Drug: Placebo Phase 2

Detailed Description:

MRG-001 is a fixed-dose combination (FDC) drug, administered as a single subcutaneous (SC) injection. Preclinical studies have demonstrated a synergistic effect of these 2 APIs in mobilizing and recruiting stem cells/immunoregulatory cells and promoting tissue regeneration in a wide variety of studies.

MRG-001 is likely to target multiple aspects of the COVID-19. MRG-001 exhibits immunoregulatory and regenerative properties in preclinical studies with a wide variety of diseases. Repairing damaged tissues in the lung and other organs, restoring the anti-virus immune system and modulating the inflammation are obvious therapeutic targets for COVID-19.

Part A has been completed in May 01, 2021.

Part B has been initiated in January 2022.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double-Blind Randomized Placebo-Controlled Trial
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIa, Adaptive, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study in Hospitalized Patients Infected With Severe and Critical SARS-CoV-2 to Assess the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of MRG-001
Actual Study Start Date : December 1, 2021
Estimated Primary Completion Date : March 31, 2022
Estimated Study Completion Date : July 1, 2022


Arm Intervention/treatment
Experimental: MRG-001
Multiple SC dose of 0.0066 mL/kg MRG-001 (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
Drug: MRG-001
Subjects will receive subcutaneous MRG-001 injections.

Placebo Comparator: Placebo
Single SC dose of 0.0066 mL/kg Sterile Injectable Saline (n=20) will be administered every other day for the duration of 13 days totaling 7 injections.
Drug: Placebo
Subjects will receive subcutaneous placebo injections.




Primary Outcome Measures :
  1. Safety and Tolerability [ Time Frame: 60 days ]
    To evaluate the safety (SAE's) of MRG-001 in Severe and Critical SARS-CoV-2 patients.


Secondary Outcome Measures :
  1. Change in percentages from baseline in circulating white blood cell subpopulations [ Time Frame: 15 days ]
  2. Change in Plerixafor concentration (ng/ml) from baseline in blood [ Time Frame: 15 days ]
  3. Change in Tacrolimus concentration (ng/ml) from baseline in blood [ Time Frame: 15 days ]
  4. Change from baseline in ALT, AST, INR, Albumin, Bilirubin, LDH, BUN, eGFR [ Time Frame: 15 days ]
  5. Change in percentages from baseline in circulating stem cells and immune cells [ Time Frame: 15 days ]
  6. All-cause mortality assessed at 14, 28 and 60 days following randomization. [ Time Frame: 60 days ]
  7. Time to clinical improvement from randomization by at least 2 points on the 8-point ordinal scale of WHO clinical improvement scale assessed up to 14 and 60 days (1=Asymptomatic, no limitations of activities; 8=death). [ Time Frame: 60 days ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Subject voluntarily agrees to participate in this study and is able to provide written informed consent or has a legal representative who can provide informed consent.
  2. Males and females over 18 years of age, inclusive, at the time of signing the ICF.
  3. Hospitalized, with COVID-19 symptoms of respiratory illness caused by SARS-CoV-2 infection (defined as Scale 5 - 7 on the WHO 8-point ordinal scale for clinical improvement.
  4. Laboratory-confirmation SARS-CoV-2 by real time polymerase chain reaction in the respiratory tract (NP swab, oropharyngeal swab, tracheal aspirate, BAL) </=14 days prior to randomization.
  5. Radiologic findings compatible with diagnosis of SARS-CoV-2 pulmonary infection.
  6. Women of childbearing potential must be willing and able to use at least one highly effective contraceptive method for a period from the screening visit until the end of study visit.
  7. Men must be willing to use a double-barrier contraception from enrollment until at 5 months after the last dose of study drug, if not abstinent.

Exclusion Criteria

1. Participation in any other clinical trial of an experimental treatment for COVID-19 (remdesivir use is permitted).

2. Significant pre-existing organ dysfunction prior to randomization

  1. Lung: Receiving supplemental home oxygen therapy at baseline for pre-existing medical condition (other than COVID-19), as documented in medical record
  2. Heart: Pre-existing congestive heart failure defined as an ejection fraction <20% as documented in the medical record. clinically significant ventricular arrhythmias (ventricular tachycardia, ventricular fibrillation), unstable angina, myocardial infarction (past 3 months), heart and coronary vessel surgery (past 3 months), significant valvular heart disease, uncontrolled arterial hypertension with systolic blood pressure >180 mm Hg and diastolic blood pressure >110 mm Hg.
  3. Renal: End-stage renal disease requiring renal replacement therapy or eGFR <30 mL/min
  4. Liver: Severe chronic liver disease defined as Child-Pugh Class C
  5. Hematologic: Baseline platelet count <50,000/mm3

    2. Concurrent treatment or prior use of drugs with actual or possible direct acting immunomodulatory activity against ARDS in COVID-19 is prohibited including JAK1/JAK2 inhibitor ruxolitinib, baricitinib and tofacitinib. However, IL-6 inhibitors such as tocilizumab, sarilumab are allowed if given >72 hours prior to first study dose. Corticosteroids are permitted throughout the study.

    3. History of splenectomy or splenomegaly (spleen weighing >750 g).

    4. Body mass index of >45 kg/m2 at screening

    5. Underlying malignancy, or other condition, with estimated life expectancy of less than two months

    6. Known family history of long QT syndrome (Torsades de Pointes) or currently taking medication that prolongs QT interval.

    7. Currently taking immunomodulating biologics (e.g., interferons, interleukin).

    8. Extracorporeal membrane oxygenation (ECMO).

    9. Use of two or more vasopressors.

    10. Female subjects who are pregnant or breastfeeding or planning to breastfeed at any time through 90 days after last dose of IP.

    11. Received a live-attenuated vaccine within 30 days prior to enrollment.

    12. Positive test for Hepatitis B surface antigen (HBsAg), Hepatitis C antibody, human immunodeficiency virus (HIV) antibody or Active tuberculosis or a history of inadequately treated tuberculosis.

    13. Ongoing immunosuppression: solid organ transplant recipients.

    14. Has used an investigational drug within 30 days prior to Screening.

    15. History of hypersensitivity to MRG-001 (plerixafor [AMD3100, 24 mg/mL]) and tacrolimus [FK506, 0.5 mg/mL]) or any of the excipients or to medicinal products with similar chemical structures.

    16. Current treatment with an anti-viral medication for COVID-19 (e.g. hydroxychloroquine, lopinavir/ritonavir), other than remdesivir.

    17. Unable to understand the protocol requirements, instructions and study related restrictions, the nature, scope and possible consequences of the clinical study.

    18. Unlikely to comply with the protocol requirements, instructions and study related restrictions, e.g., uncooperative attitude, inability to return for follow-up visits and improbability of completing the clinical study.

    19. Previously been enrolled in this clinical study.

    20. Vulnerable subjects defined as individuals whose willingness to volunteer in a clinical study may be unduly influenced by the expectation, whether justified or not, of benefits associated with participation, or of a retaliatory response from senior members of a hierarchy in case of refusal to participate (e.g., persons in detention, minors and those incapable of giving consent).

    21. Any condition that in the opinion of the treating physician will increase the risk for the participant.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04646603


Contacts
Layout table for location contacts
Contact: Ali R Ahmadi, MD PhD +14437598563 info@medregenco.com
Contact: James Burdick, MD +14437598563 info@medregenco.com

Locations
Layout table for location information
United States, Maryland
Johns Hopkins Medicine Recruiting
Baltimore, Maryland, United States, 21205
Contact: Sherry Leung         
Sponsors and Collaborators
MedRegen LLC
ICON plc
Johns Hopkins University
Investigators
Layout table for investigator information
Principal Investigator: Russell N Wesson, M.B.Ch.B Johns Hopkins University
Layout table for additonal information
Responsible Party: MedRegen LLC
ClinicalTrials.gov Identifier: NCT04646603    
Other Study ID Numbers: MRG2020
First Posted: November 30, 2020    Key Record Dates
Last Update Posted: February 15, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Participants will be given a unique unidentifiable study ID number and all data will be recorded according to unidentifiable number to protect patients personal health information.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Distress Syndrome
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Respiration Disorders